ARQT — Arcutis Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00- $2.63bn
- $2.52bn
- $376.07m
Annual income statement for Arcutis Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 3.69 | 59.6 | 197 | 376 |
| Cost of Revenue | |||||
| Gross Profit | — | 2.93 | 54.6 | 177 | 339 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 207 | 305 | 301 | 325 | 388 |
| Operating Profit | -207 | -302 | -241 | -128 | -12.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -206 | -311 | -259 | -139 | -15 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -206 | -311 | -262 | -140 | -16.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -206 | -311 | -262 | -140 | -16.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -206 | -311 | -262 | -140 | -16.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.18 | -5.66 | -3.78 | -1.16 | -0.127 |